<DOC>
	<DOCNO>NCT02558114</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety recurrence rate two therapeutic strategy ribavirin patient chronic hepatitis E severe acute hepatitis E : fix duration treatment 12 week vs variable duration depend viremia within 4 week start treatment ( 12 vs 24 week ) . The purpose study also improve safety treatment Ribavirin optimize dose adjust renal function , plasma level drug hemoglobin .</brief_summary>
	<brief_title>Ribavirin Severe Acute Chronic Hepatitis E Virus Infection .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Age equal great 18 year . To comply follow diagnosis : chronic Hepatitis E : HEV RNA detectable patient elevate transaminase level least 6 month / HEV RNA detectable two separated determination interval six month . severe acute Hepatitis E : alanine aminotransferase ( ALT ) level great 10 time normal limit , HEV RNA positive , sign acute liver injury ( International normalize ratio ( INR &gt; 1.5 ) ) ; extrahepatic manifestation liver failure patient previous liver disease . Signed informed consent Terminal illness expect life expectancy le 6 month Patients contraindication treatment Ribavirin : pregnancy lactation . Severe hepatic impairment decompensated cirrhosis . hemoglobinopathy ( thalassemia , sickle cell anemia ) . history severe preexist cardiac disease , include unstable heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>